Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors

Bioorg Chem. 2022 Apr:121:105643. doi: 10.1016/j.bioorg.2022.105643. Epub 2022 Jan 25.

Abstract

As a member of Bcl-2 protein family, myeloid cell leukemia-1 (Mcl-1) plays a critical role in cell apoptosis and has become a promising anti-cancer drug target. Herein, we designed and synthesized a series of hydantoin derivatives as novel Mcl-1 inhibitors based on our previously developed lead compound. Among them, compound M23 and M24 exhibited good binding affinities against Mcl-1 with Ki values of 0.49 μM and 0.33 μM respectively. Especially, compound M23 exhibited good selectivity over Bcl-xL, whereas compound M24 possessed good selectivity over both Bcl-2 and Bcl-xL. Furthermore, we also investigated the effects of these new Mcl-1 inhibitors on cell proliferation, apoptosis and mitochondrial membrane potential, as well as the stability in plasma.

Keywords: Apoptosis; Cancer; Hydantoin derivatives; Mcl-1 inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / chemistry
  • Apoptosis
  • Cell Line, Tumor
  • Drug Design
  • Hydantoins* / pharmacology
  • Myeloid Cell Leukemia Sequence 1 Protein / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism

Substances

  • Antineoplastic Agents
  • Hydantoins
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Proto-Oncogene Proteins c-bcl-2